Title
Category
Credits
Event date
Cost
Addressing the Cardiometabolic Risk Continuum in MASH: What Clinicians Need to Know
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex condition rooted in metabolic disturbances and often coexists with obesity, prediabetes, type 2 diabetes, and cardiovascular disease. Stemming from metabolic dysfunction-associated steatotic liver disease (MASLD), MASH is closely linked to cardiometabolic risk factors and pre-existing cardiovascular conditions. MASH is a gradually advancing and often asymptomatic liver disease that necessitates early detection and diagnosis.
Clinical Brief: Advancements in Dyslipidemia Treatments and ASCVD Risk Reduction for High-Risk Individuals
  • CMHC
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 CDE
  • 0.50 Participation
$0.00
This clinical brief was developed from a presentation at the 19th CMHC Annual Congress held from October 17-19, 2024 in Boston, MA. The session, “Evolving Therapies in Dyslipidemia and ASCVD Risk Reduction: Putting It All Together in High-Risk Patients,” was presented by Dr. Pamela B. Morris, Professor of Medicine, Cardiology from The Medical University of South Carolina, Charleston, SC, supported by an educational grant from Esperion Therapeutics.
Addressing Unmet Needs and Disease Burden in Chronic Spontaneous Urticaria: A Clinical Escape Room Challenge
  • LivDerm
  • TME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Participation
$0.00
Chronic spontaneous urticaria (CSU) has unpredictable symptoms without an obvious external cause; however, the symptoms of CSU, such as hives, itching and swelling, mimic an allergic reaction, and there is often significant time spent finding an external trigger. Despite current treatment options for CSU, treatment resistance and poor symptom control remain significant challenges; only 40% of patients achieve complete symptom control with standard therapy.
Navigating Cardiorenal Metabolic Complexities: A Case Study of a 64-Year-Old Female with T2D, HTN, CKD, and Obesity
  • CMHC
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 CDE
  • 0.50 Participation
$0.00
This interactive case-based program focuses on managing patients with cardiorenal metabolic comorbidities. Participants will explore evidence-based guidelines, therapeutic strategies, and risk assessment tools to improve cardiovascular and kidney outcomes in patients with CKD, type 2 diabetes, and cardiovascular disease. Engaging decision-making scenarios and expert-led discussions will enhance practical skills and interdisciplinary approaches to optimize patient care.
JAK is Out of the Box: Leveling Up Care for Severe Alopecia Areata Across Patient Populations
  • LivDerm
  • TME
  • 0.75 AAPA Category I CME
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Severe alopecia areata (AA) causes a significant disease burden impacting multiple aspects of patients’ health, quality of life, and daily functioning. New treatment options, including Janus kinase (JAK) inhibitors, are becoming available, but diagnosis and management can be challenging, especially for pediatric patients and those with skin of color.
Trading Steroids for Targeted Topical Therapies: Clinical Pearls for Your AD, Psoriasis, and Seborrheic Dermatitis Patients
  • LivDerm
  • TME
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Participation
$0.00
While corticosteroids hold a valuable place in the therapeutic toolkit for atopic dermatitis, psoriasis, seborrheic dermatitis, and similar conditions, targeted topical therapies may offer better options for individualized care. Non-steroidal targeted therapies allow for better efficacy, improved safety, long-term use, and treatment of sensitive regions of the skin. Health care professionals require expert guidance on clinical data for new and emerging targeted topical therapies and strategies for utilizing them to improve outcomes in adult and pediatric patients.
Expanding the AD Toolb-OX: A New Pathway for Treating Moderate-to-Severe Disease
  • LivDerm
  • TME
  • 0.75 AAPA Category I CME
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
The management of moderate-to-severe AD remains challenging due to high disease burden and disease heterogeneity, highlighting the need for more broadly targeted therapeutics. The OX40-OX40L pathway has been identified as a potential therapeutic target for improving outcomes in heterogenous disease.

Pages